A. Sinclair Dunlop, Director at Apellis Pharmaceuticals, Inc. (APLS), sold 500 shares at $50.70 ($25K) on 2023-01-03, disclosed to the SEC on 2023-01-05.
Scheduled sale ($25k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| APLS | SELL | 2025-09-19 | $1.4M | — | Filing → |
| APLS | SELL | 2024-09-17 | $2.7M | — | Filing → |
| APLS | SELL | 2024-06-21 | $2.9M | — | Filing → |